Meredith Cook Sells 500 Shares of ANI Pharmaceuticals (NASDAQ:ANIP) Stock

ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) VP Meredith Cook sold 500 shares of the stock in a transaction dated Monday, July 13th. The shares were sold at an average price of $81.84, for a total transaction of $40,920.00. Following the sale, the vice president directly owned 77,390 shares in the company, valued at $6,333,597.60. This trade represents a 0.64% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Meredith Cook also recently made the following trade(s):

• On Friday, June 12th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $82.03, for a total transaction of $41,015.00.
• On Wednesday, May 13th, Meredith Cook sold 500 shares of ANI Pharmaceuticals stock. The stock was sold at an average price of $78.16, for a total transaction of $39,080.00.

ANI Pharmaceuticals Trading Up 0.3%

Shares of NASDAQ ANIP opened at $80.82 on Thursday. The firm’s 50 day moving average price is $81.47 and its 200-day moving average price is $79.52. ANI Pharmaceuticals, Inc. has a 52-week low of $62.60 and a 52-week high of $99.50. The company has a debt-to-equity ratio of 1.06, a quick ratio of 2.52 and a current ratio of 3.12. The company has a market cap of $1.84 billion, a PE ratio of 20.46 and a beta of 0.43.

ANI Pharmaceuticals (NASDAQ:ANIP) last announced its quarterly earnings results on Friday, May 8th. The specialty pharmaceutical company reported $2.05 earnings per share for the quarter, beating the consensus estimate of $1.28 by $0.77. ANI Pharmaceuticals had a net margin of 9.98% and a return on equity of 27.51%. The company had revenue of $237.46 million during the quarter, compared to the consensus estimate of $207.63 million. During the same quarter last year, the firm earned $1.70 earnings per share. The firm’s quarterly revenue was up 20.5% compared to the same quarter last year. ANI Pharmaceuticals has set its FY 2026 guidance at 9.190-9.690 EPS. On average, equities research analysts expect that ANI Pharmaceuticals, Inc. will post 8.03 EPS for the current fiscal year.

Institutional Investors Weigh In On ANI Pharmaceuticals

A number of large investors have recently added to or reduced their stakes in ANIP. Divisadero Street Capital Management LP purchased a new stake in ANI Pharmaceuticals during the third quarter valued at approximately $21,454,000. Vanguard Group Inc. boosted its stake in shares of ANI Pharmaceuticals by 2.2% during the 4th quarter. Vanguard Group Inc. now owns 1,305,068 shares of the specialty pharmaceutical company’s stock worth $103,022,000 after acquiring an additional 27,598 shares during the last quarter. Oliver Luxxe Assets LLC purchased a new position in shares of ANI Pharmaceuticals during the 4th quarter worth $1,823,000. Penn Capital Management Company LLC grew its position in shares of ANI Pharmaceuticals by 2,058.9% during the 4th quarter. Penn Capital Management Company LLC now owns 137,394 shares of the specialty pharmaceutical company’s stock valued at $10,858,000 after acquiring an additional 131,030 shares during the period. Finally, Artemis Investment Management LLP bought a new stake in shares of ANI Pharmaceuticals during the 4th quarter valued at $1,706,000. Institutional investors own 76.05% of the company’s stock.

Analyst Upgrades and Downgrades

Several research analysts have recently weighed in on ANIP shares. Guggenheim restated a “buy” rating and issued a $124.00 price target on shares of ANI Pharmaceuticals in a research note on Friday, July 10th. Wall Street Zen raised ANI Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. Zacks Research downgraded ANI Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Thursday, May 14th. Finally, Weiss Ratings raised ANI Pharmaceuticals from a “hold (c+)” rating to a “buy (b-)” rating in a research report on Tuesday, June 23rd. Six analysts have rated the stock with a Buy rating and two have given a Hold rating to the stock. According to data from MarketBeat, ANI Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $107.33.

ANI Pharmaceuticals Company Profile

ANI Pharmaceuticals, Inc is a United States–based specialty pharmaceutical company focused on the development, manufacturing and commercialization of generic and branded prescription drugs. The company operates as an end-to-end provider, offering services that range from active pharmaceutical ingredient (API) production and formulation development to finished dosage form manufacturing and packaging.

ANI’s product portfolio encompasses injectable and oral therapies across several therapeutic areas, including endocrinology, oncology, pain management and respiratory care.